Date

January 8, 2017Array

Sector

Healthcare

Deal Type

M&A

Deal Value

$75M

GCA Advises Takara Bio USA Holdings on its Acquisition of Rubicon Genomics

We are pleased to announce that our client, Takara Bio USA Holdings, Inc. (“TBUSH”) and Rubicon Genomics, Inc. (“Rubicon”), signed a merger agreement pursuant to which TBUSH will acquire Rubicon, a privately-owned company headquartered in Ann Arbor, Michigan, for $75 million. Rubicon is a leading provider of pre-analytical library preparation kits that increase the accuracy, efficiency and speed of genomic analysis. TBUSH is a wholly-owned subsidiary of Takara Bio Inc., a leading global biotechnology and life science company headquartered in Shiga, Japan.

The transaction is subject to customary closing conditions. GCA acted as exclusive financial advisor to TBUSH in connection with this transaction.

Previous Next
All transactions